Distinguished in Temporal Arteritis

Hendrik Koops-Schulze

Munich, BY, DE 
Distinguished in Temporal Arteritis
Munich, BY, DE 
OverviewLocationsClinical Research

Overview

Hendrik Koops-Schulze practices in Munich, Germany. Mr. Koops-Schulze is rated as a Distinguished expert by MediFind in the treatment of Temporal Arteritis. His top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Synovitis, and Severe Acute Respiratory Syndrome (SARS).

His clinical research consists of co-authoring 226 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 21 articles in the study of Temporal Arteritis.

Gender
Male

Locations

Munich, BY 80336, Germany
Other Locations
Altona, HH, Germany
Heidelberg, BW, Germany
Bayern, BY, Germany
Berlin, BE 10179, Germany
Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Study Protocol for a Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's Disease (AOSD) Including an Open-label Long Term Extension
Study Protocol for a Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's Disease (AOSD) Including an Open-label Long Term Extension
Enrollment Status: Terminated
Publish Date: August 07, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

225 Total Publications

Telangiectasias as a Forerunner of Pulmonary Hypertension.
Telangiectasias as a Forerunner of Pulmonary Hypertension.
Journal: Deutsches Arzteblatt international
Published: September 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Koops-Schulze's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 41 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile